Latest news with #MarksansPharmaLimited
Business Upturn
30-05-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
15-05-2025
- Business
- Business Upturn
Marksans Pharma's UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution
By News Desk Published on May 15, 2025, 09:26 IST Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution. The regulatory approval marks a significant addition to the company's neurology-focused portfolio in the UK market. Gabapentin is commonly prescribed for the treatment of nerve pain and epilepsy. Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. Its facilities in India, the US, and the UK are approved by major global regulatory bodies including the USFDA, UKMHRA, and TGA Australia. The company's portfolio spans key therapeutic areas including cardiovascular, central nervous system (CNS), anti-diabetics, pain management, gastroenterology, and anti-allergy segments. Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions. News desk at
Business Upturn
28-04-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary receives one USFDA observation after cGMP inspection at New York facility
Marksans Pharma Limited has announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of its wholly owned subsidiary, Time-Cap Laboratories, Inc. The facility is located at 7 Michael Avenue, Farmingdale, New York, USA. The inspection took place from 16th April 2025 to 24th April 2025. Upon conclusion, Time-Cap Laboratories, Inc. received one inspectional observation through Form 483. Notably, there were no data integrity-related observations reported during the inspection. Marksans Pharma stated that Time-Cap Laboratories, Inc. is committed to addressing the observation comprehensively and will work closely with the USFDA to ensure timely compliance within the stipulated deadlines. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
